FDA-approved corneal collagen cross-linking is barely a year old (in the United States). The Avedro KXL UV system, along with Photrexa and Photrexa Viscous, is approved for patients aged 14 and up with progressive keratoconus or post-surgical ectasia. After years of commercial use abroad, this long-awaited therapeutic option has the potential to halt vision loss for many patients in the United States. In this article, corneal experts discuss the impact that cross-linking has had on their practices, as well as how they combine cross-linking with other procedures.
